INNOSPEC INC.(IOSP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,484 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
IOSP Stock Analysis & AI Quality Score
AI stock analysis and institutional research for INNOSPEC INC. (IOSP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IOSP at 50.0/100 on a 32-signal composite quality model, placing it at rank #1,484 of 2,879 stocks — the bottom half of the AI-ranked universe. IOSP scores in the top quartile across institutional flow (75.7). Areas of concern include revenue growth (19.4) and earnings quality (21.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), INNOSPEC INC. reports quarterly revenue of $453.2M, net income of $30.4M, an operating margin of 8.1%. Top institutional holders of IOSP by reported 13-F value include BlackRock,, Allspring Global Investments Holdings,, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. IOSP trades on the Nasdaq exchange and files with the SEC under CIK 1054905. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IOSP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INNOSPEC INC. directly from SEC EDGAR. INNOSPEC INC.'s 13F Pro composite quality score has ranged between 8 and 70 since 2021, currently 50.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q1 2026
$453.2M
Net Income
Q1 2026
$30.4M
Free Cash Flow
Q1 2026
$17.6M
Operating Margin
Q1 2026
8.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-5.3% YoYOperating Income
+10.1% YoYEPS (Diluted)
-74.5% YoYTotal Assets
+1.6% YoYTotal Debt
Op. Cash Flow
-11.0% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $1.85B -5.3% | $1.95B -0.8% | $1.96B +32.4% | $1.48B +24.3% | $1.19B -21.2% | $1.51B |
| Operating Income | $177.9M +10.1% | $161.6M -13.7% | $187.3M +41.8% | $132.1M +292.0% | $33.7M -77.5% | $149.9M |
| EPS (Diluted) | $1.42 -74.5% | $5.56 +4.5% | $5.32 +41.9% | $3.75 +223.3% | $1.16 -74.4% | $4.54 |
| Total Assets | $1.73B +1.6% | $1.71B +6.5% | $1.60B +2.1% | $1.57B +12.4% | $1.40B -4.9% | $1.47B |
| Total Debt | — | — | — | — | $0.00 -100.0% | $58.6M |
| Operating Cash Flow | $184.5M -11.0% | $207.3M +153.7% | $81.7M -12.3% | $93.2M -36.1% | $145.9M -9.7% | $161.6M |
AI Insight: IOSP Financial Trends
Operating income collapsed to $6M in Q3 2025 before rebounding to $47M in Q4 2025, masking persistent revenue stagnation around $440–$456M.
• Revenue has been essentially flat, ranging narrowly from $435M in Q2 2024 to $453M in Q1 2026 — no meaningful growth over eight quarters.
• Operating income dropped sharply to $6M in Q3 2025 from $42M in Q1 2025, then recovered to $47M in Q4 2025 and $36M in Q1 2026.
• Equity has grown steadily from $1,193M in Q2 2024 to $1,345M in Q1 2026, suggesting retained earnings accumulation despite volatile operating income.
• Operating cash flow is highly volatile — peaking at $74M in Q3 2024, falling to $5M in Q2 2024, and most recently $18M in Q1 2026.
⚠ The Q3 2025 operating income plunge to $6M — versus a $41–$47M range otherwise — warrants explanation; recurrence would be a significant red flag.
⚠ Operating cash flow of only $18M in Q1 2026 despite $36M operating income signals meaningful working capital drag worth monitoring.
⚠ Total debt data is absent across all periods; leverage profile remains unknown, limiting full balance-sheet assessment.
AI Insight: IOSP Ratio Trends
INNOSPEC's profitability has deteriorated sharply from mid-2024 peaks, with ROIC falling from 14.7% in Q3 2024 to 10.9% in Q1 2026.
• Operating margin peaked at 10.3% in Q3 2024, then collapsed to 1.3% in Q3 2025 before partially recovering to 8.1% in Q1 2026.
• ROIC declined from a high of 14.7% in Q3 2024 to 10.9% in Q1 2026, a 380bp contraction over five quarters.
• Q4 2025 showed a sharp rebound in both operating margin (10.3%) and ROIC (14.1%), suggesting Q3 2025 weakness may have been a one-off.
⚠ TTM operating margin of 6.9% significantly lags the Q1 2026 quarterly rate of 8.1%, indicating lingering drag from Q3 2025's 1.3% print.
⚠ With D/E, NPM, ROE, and ROA data largely absent across quarters, assessing balance sheet health and net profitability trends remains difficult.
⚠ Whether Q3 2025's margin collapse was truly isolated or signals structural pressure on earnings warrants close monitoring in coming quarters.
Get alerted when IOSP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for INNOSPEC INC. including:
Top Institutional Holders of IOSP
BlackRock, Inc.
$283.2M3,878,975 shAllspring Global Investments Holdings, LLC
$170.5M2,315,942 shVANGUARD PORTFOLIO MANAGEMENT LLC
$135.8M1,860,091 shDIMENSIONAL FUND ADVISORS LP
$90.7M1,242,089 shVANGUARD CAPITAL MANAGEMENT LLC
$81.4M1,114,598 shSTATE STREET CORP
$70.4M964,335 shVICTORY CAPITAL MANAGEMENT INC
$63.2M864,994 shNuveen, LLC
$47.0M643,248 shGEODE CAPITAL MANAGEMENT, LLC
$46.1M630,592 shTWO SIGMA INVESTMENTS, LP
$43.3M593,039 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $283.2M | 3,878,975 |
| Allspring Global Investments Holdings, LLC | $170.5M | 2,315,942 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $135.8M | 1,860,091 |
| DIMENSIONAL FUND ADVISORS LP | $90.7M | 1,242,089 |
| VANGUARD CAPITAL MANAGEMENT LLC | $81.4M | 1,114,598 |
| STATE STREET CORP | $70.4M | 964,335 |
| VICTORY CAPITAL MANAGEMENT INC | $63.2M | 864,994 |
| Nuveen, LLC | $47.0M | 643,248 |
| GEODE CAPITAL MANAGEMENT, LLC | $46.1M | 630,592 |
| TWO SIGMA INVESTMENTS, LP | $43.3M | 593,039 |
More Healthcare Companies
View all Healthcare →Put IOSP on your watchlist
Track score changes the day INNOSPEC INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IOSP a good stock to buy?
13F Pro's AI-powered analysis of INNOSPEC INC. (IOSP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IOSP are available on the IOSP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own IOSP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IOSP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INNOSPEC INC.'s investment landscape.